Inhibikase Therapeutics, Inc. provided notice on December 2, 2024, to terminate its At-the-Market Offering Agreement (ATM Agreement) with H.C. Wainwright & Co., LLC. The termination is effective December 11, 2024.
Under the ATM Agreement, the company had previously sold 315,338 shares of its common stock, generating an aggregate gross sales price of $849,187.85. On May 20, 2024, the maximum aggregate gross sales price that could be offered under the agreement was reduced to $50,000.
No sales of the company's common stock have occurred pursuant to the ATM Agreement since May 20, 2024. The termination formally concludes this financing mechanism for Inhibikase Therapeutics.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.